|
YIPF6 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.77130010448457E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.47669999853662E-08 |
| Normal-vs-Stage2 |
9.633300E-04 |
| Normal-vs-Stage3 |
6.18789464112979E-11 |
| Normal-vs-Stage4 |
3.65480001818241E-09 |
| Stage1-vs-Stage2 |
3.725400E-01 |
| Stage1-vs-Stage3 |
5.562200E-02 |
| Stage1-vs-Stage4 |
5.182300E-02 |
| Stage2-vs-Stage3 |
3.360000E-02 |
| Stage2-vs-Stage4 |
3.697600E-02 |
| Stage3-vs-Stage4 |
7.052400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.53479509288491E-11 |
| Normal-vs-AfricanAmerican |
3.236000E-03 |
| Normal-vs-Asian |
4.80299999772171E-08 |
| Caucasian-vs-AfricanAmerican |
1.860440E-01 |
| Caucasian-vs-Asian |
5.272600E-01 |
| AfricanAmerican-vs-Asian |
9.103500E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.12120321307907E-11 |
| Normal-vs-Female |
2.59850000405848E-08 |
| Male-vs-Female |
2.306000E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.47229999992416E-07 |
| Normal-vs-Age(41-60Yrs) |
1.38720002151871E-09 |
| Normal-vs-Age(61-80Yrs) |
7.53920004203934E-09 |
| Normal-vs-Age(81-100Yrs) |
3.077900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.197200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.978400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.701000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.582000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.074800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.743400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.383780E-02 |
| Classical-VS-Follicular |
1.191000E-01 |
| Classical-VS-Other |
7.073900E-02 |
| Classical-VS-Normal |
7.25279947211277E-10 |
| Tall-VS-Follicular |
2.203300E-03 |
| Tall-VS-Other |
2.388400E-01 |
| Tall-VS-Normal |
4.4397996390444E-10 |
| Follicular-VS-Other |
5.897700E-03 |
| Follicular-VS-Normal |
1.078300E-03 |
| Other-VS-Normal |
8.32460000000923E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.11649999748431E-08 |
| Normal-vs-N1 |
8.14080003408435E-09 |
| N0-vs-N1 |
6.858500E-02 |
|
|
